


- R<sub>4</sub> and R<sub>5</sub> are taken separately, are identical, and are (C<sub>1</sub>-C<sub>6</sub>)alkyl; or
- R<sub>4</sub> and R<sub>5</sub> are taken separately, are different, and are aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl or (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl(C<sub>1</sub>-C<sub>6</sub>)alkyl; or
- R<sub>4</sub> and R<sub>5</sub> are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7-membered saturated or partially unsaturated ring, said ring optionally containing one to three hetero atoms selected from O, S and N, said ring being optionally substituted with (C<sub>1</sub>-C<sub>6</sub>)alkyl, hydroxy or (C<sub>1</sub>-C<sub>6</sub>)alkoxy, said ring being optionally bridged with a (C<sub>1</sub>-C<sub>6</sub>)alkyl which may be gem-di(C<sub>1</sub>-C<sub>6</sub>)alkylated or substituted with one to three hydroxy, oxo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, phenyl(C<sub>1</sub>-C<sub>6</sub>)alkyl or CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>, said ring being optionally fused via two adjacent atoms shared with another ring selected from phenyl and heteroaryl, said heteroaryl ring containing four to eight carbon atoms which may be optionally replaced with one to three hetero atoms selected from O, S and N;

m is 0, 1 or 2;

R<sub>8</sub> is (C<sub>1</sub>-C<sub>6</sub>)alkyl, said alkyl being optionally substituted with one to three halogen;


-Q<sub>1</sub>- is a bond, -O-,



-Q<sub>2</sub>- is:

- a) -(CH<sub>2</sub>)<sub>q</sub>;
- b) -(CH<sub>2</sub>-CH<sub>2</sub>-O)<sub>r</sub>;

-Q<sub>3</sub> is: -H, -OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, -O-CO-X<sub>3</sub>, -NHX<sub>3</sub>, or



R<sub>1</sub> is (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three halogen, hydroxy, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;

R<sub>2</sub> and R<sub>3</sub> are taken separately and are independently (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three hydroxy, halogen, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;  
or

R<sub>2</sub> and R<sub>3</sub> are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7- membered ring, said ring containing one to three O, S or N, said ring being optionally bridged with a (C<sub>1</sub>-C<sub>6</sub>)alkyl which may be gem-dialkylated or substituted with one to three hydroxy, oxo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;

n is 1, 2, 3, 4 or 5;

Ar is a 5- or 6-membered aromatic ring containing 0 to 3 hetero atoms selected from O, S and N;

Y<sub>1</sub>, Y<sub>2</sub> and Y<sub>3</sub> are independently

- hydrogen, hydroxy, mercapto, amino, nitro, halogen, -NHR<sub>1</sub>, -NR<sub>2</sub>R<sub>3</sub>,
- (CH<sub>2</sub>)<sub>S</sub>CN or -(CH<sub>2</sub>)<sub>S</sub> CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;
- (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -S(O)<sub>m</sub>R<sub>8</sub>;

s is 0, 1, 2, 3, 4, 5 or 6 ;

p is 0, 1, 2 or 3;

Z<sub>1</sub> is CH, N, O or S;

q is 0, 1, 2, 3, or 4;

r is 2, 3, or 4; and

X<sub>3</sub> and X<sub>4</sub> are taken separately and are independently (C<sub>1</sub>-C<sub>6</sub>)alkyl; or

X<sub>3</sub> and X<sub>4</sub> are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7-membered ring, said ring containing one to three additional hetero atoms selected from O, S and N;


a racemic or isomeric form thereof or a pharmaceutically acceptable salt of said compound, racemic or isomeric form.

36. (Previously presented): A compound of claim 35 wherein A<sub>1</sub> is O; X<sub>1</sub> is H; X<sub>2</sub> is halogen, amino, (C<sub>1</sub>-C<sub>6</sub>)alkyl, hydroxy or -NHR<sub>1</sub>; and

R is

-(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, aryl(C<sub>2</sub>-C<sub>6</sub>)alkynyl or 2-, 3- or 4-pyridyl(C<sub>1</sub>-C<sub>6</sub>)alkyl group optionally substituted on said pyridyl ring with (C<sub>1</sub>-C<sub>6</sub>)alkyl, halogen or hydroxy; or

R is




n is 1, 2 or 3;

Y<sub>1</sub>, Y<sub>2</sub> and Y<sub>3</sub> are each independently H or (C<sub>1</sub>-C<sub>6</sub>)alkoxy; or

Y<sub>1</sub> and Y<sub>2</sub> are each H; and Y<sub>3</sub> is (C<sub>1</sub>-C<sub>6</sub>)alkoxy, amino, -NHR<sub>1</sub>, -NR<sub>2</sub>R<sub>3</sub>, nitro, hydroxy, -(CH<sub>2</sub>)<sub>5</sub>CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>, -(CH<sub>2</sub>)<sub>5</sub>-CN, or (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three halogen; or

Y<sub>1</sub> is H; and Y<sub>2</sub> and Y<sub>3</sub> are each independently hydroxy, halogen or (C<sub>1</sub>-C<sub>6</sub>)alkoxy; or

R is




Y1, Y2 and Y3 are each H ; or

Y1 and Y2 are each H and Y3 is (C<sub>1</sub>-C<sub>6</sub>)alkoxy or halogen.

37. (Previously presented): A compound of claim 36 wherein X<sub>1</sub> is H;  
X<sub>2</sub> is halogen, amino, (C<sub>1</sub>-C<sub>6</sub>)alkyl, hydroxy or -NHR<sub>1</sub>;

R is



n is 1, 2 or 3;

Y1, Y2 and Y3 are each H or (C<sub>1</sub>-C<sub>6</sub>)alkoxy; or

Y1 and Y2 are each H; and Y3 is

(C<sub>1</sub>-C<sub>6</sub>)alkoxy;

amino;

-NHR<sub>1</sub>;

-NR<sub>2</sub>R<sub>3</sub>;

nitro;

hydroxy;


(C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three halogen;

-(CH<sub>2</sub>)<sub>s</sub>CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub> in which s is 0 or 1; Q<sub>1</sub> is O, -NH- or a bond; Q<sub>2</sub> is -  
(CH<sub>2</sub>)<sub>q</sub>-, wherein q is 0, 1, 2, 3 or 4; and Q<sub>3</sub> is H, OH or -NX<sub>3</sub>X<sub>4</sub>; or

-(CH<sub>2</sub>)<sub>s</sub>-CN wherein s is 0 or 1; or

Y1 is H; and Y2 and Y3 are each independently hydroxy, halogen or (C<sub>1</sub>-C<sub>6</sub>)alkoxy; or

R is




Ar<sub>1</sub> is a 6-membered aromatic ring optionally containing N in the 2-, 3- or 4-position;

Y1, Y2 and Y3 are each H; or,

when Ar<sub>1</sub> does not contain N, then Y1 and Y2 are each H and Y3 is (C<sub>1</sub>-C<sub>6</sub>)alkoxy or halogen.

38. (Previously presented): A compound of claim 37 wherein said (C<sub>1</sub>-C<sub>6</sub>)alkyl is 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 1-trifluoromethylethyl, 4,4,4-trifluoro-n-butyl, 2-trifluoromethylpropyl, 1-trifluoromethylpropyl, 1-methyl-1-trifluoromethylethyl, 3,3,3-trifluoro-1-methylpropyl, 2,2,2-trifluoroethoxy, 3,3,3-trifluoropropoxy, 1-trifluoromethylethoxy, 4,4,4-trifluoro-n-butoxy, 2-trifluoromethylpropoxy, 1-trifluoromethylpropoxy, 1-methyl-1-trifluoromethylethoxy, 3,3,3-trifluoro-1-methylpropoxy, 2,2,2-trifluoroethylthio, 3,3,3-trifluoropropylthio, 1-trifluoromethylethylthio, 4,4,4-trifluoro-n-butylthio, 2-trifluoromethylpropylthio, 1-trifluoromethylpropylthio, 1-methyl-1-trifluoromethylethylthio, or 3,3,3-trifluoro-1-methylpropylthio.

39. (Previously presented): A compound of claim 35 wherein X<sub>1</sub> and X<sub>2</sub> are independently H, hydroxy, halogen, amino, nitro, mercapto, cyano, carboxyl, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -S(O)<sub>m</sub>R<sub>8</sub>;  
R is



wherein

Y1, Y2 and Y3 are independently

H, hydroxy, mercapto, amino, -NHR<sub>1</sub>, -NR<sub>2</sub>R<sub>3</sub>, nitro, halogen, -(CH<sub>2</sub>)<sub>s</sub>CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>, (CH<sub>2</sub>)<sub>s</sub>-CN, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, or -S(O)<sub>m</sub>R<sub>8</sub>;

R<sub>4</sub> and R<sub>5</sub> are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7-membered saturated or partially saturated ring containing one to three O, S or N, said ring being optionally bridged with (C<sub>1</sub>-C<sub>6</sub>)alkyl which may be gem-dialkylated or substituted with one to three hydroxy, oxo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, phenyl(C<sub>1</sub>-C<sub>6</sub>)alkyl or CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>.

40. (Previously presented): A compound of claim 39 which is 1-dimethylamino-7-methyl-4-(3-pyrid-3-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one; 4-(3,4-dimethoxybenzyl)-7-methyl-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-(1-dimethylamino-7-methyl-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
7-bromo-1-dimethylamino-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-methyl-4-(3-phenylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(7-bromo-1-dimethylamino-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
1-azepan-1-yl-7-methyl-4-pyrid-3-ylmethyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(7-methyl-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
1-dimethylamino-methyl-((E)-3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile; or  
1-azepan-1-yl-7-bromo-4-(3,4-dimethoxybenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one.

41. (Previously presented): A compound of claim 35 which is  
1-(azepan-1-yl)-7-chloro-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-3-(3-phenylallyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-1-dimethylamino-4-((E)-3-pyrid-3-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-pyrid-3-ylmethyl-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-3-pyrid-3-ylmethyl-1-pyrrolidin-1-yl-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-allyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(4-methylbenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(2-chlorobenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(3-chlorobenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(4-chlorobenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(4-bromobenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(4-fluorobenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(4-(trifluoromethyl)benzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(4-cyanobenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(azepan-1-yl)-7-chloro-4-(2-methoxybenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(3-methoxybenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(4-methoxybenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(3,4-dichlorobenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(3,4-dimethoxybenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(2-pyridylmethyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(3-pyridylmethyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(4-pyridylmethyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(2-phenylethyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-[2-(4-methoxyphenyl)ethyl]-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(3-phenylpropyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-7-chloro-4-(2-oxo-2-phenylethyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-[2-(4-methoxyphenyl)-2-oxoethyl]-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-[2-(4-chlorophenyl)-2-oxoethyl]-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
5-[(1-(azepan-1-yl)-7-chloro-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-yl)acetyl]-2-methoxybenzoic acid methyl ester;  
7-chloro-4-pyrid-3-ylmethyl-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-bromo-4-(4-chlorophenylmethyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-7-bromo-4-(4-fluorobenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(1-azepan-1-yl-7-bromo-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
1-azepan-1-yl-7-bromo-4-(3,4-dimethoxybenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;



1-(azepan-1-yl)-7-bromo-4-(3-pyridinylmethyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(azepan-1-yl)-7-bromo-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-azepan-1-yl-7-bromo-4-[3-(4-chlorophenyl)-allyl]-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-azepan-1-yl-7-bromo-4-[3-(4-methoxyphenyl)-allyl]-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-azepan-1-yl-7-bromo-4-((E)-3-pyrid-3-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-azepan-1-yl-7-bromo-4-(3-pyrid-4-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-(4-methylbenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-(4-chlorobenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-(4-fluorobenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

3-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;

4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;

4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzoic acid methyl ester;

7-bromo-4-(4-nitrobenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-(4-methoxybenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

acetic acid 4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl ester;

7-bromo-4-(4-hydroxybenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-(3,4-dimethoxybenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-benzo[1,3]dioxol-5-ylmethyl-7-bromo-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-(3,5-dimethoxybenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-1-pyrrolidin-1-yl-4-(3,4,5-trimethoxybenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

[4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetic acid;  
1-(pyrrolidin-1-yl)-7-bromo-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(3-phenylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-[(E)-3-(4-chlorophenyl)-allyl]-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-[3-(4-methoxyphenyl)-allyl]-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(3-pyrid-3-ylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-((E)-3-pyrid-4-ylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(1H-imidazol-4-ylmethyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(3,5-dimethyl-isoxazol-4-ylmethyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-cyclopentylmethyl-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-butyl-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-1-pyrrolidin-1-yl-4-(2,2,2-trifluoroethyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(2-hydroxyethyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(2-diethylaminoethyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-prop-2-ynyl-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(2-phenoxyethyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(2-phenylsulphenylethyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-yl)phenylacetic acid methyl ester;  
4-(7-bromo-5-oxo-1-piperid-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
7-bromo-4-(3,4-dimethoxybenzyl)-1-piperid-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(piperid-1-yl)-7-bromo-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-(3-pyrid-3-ylallyl)-1-thiomorpholin-4-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-1-dimethylamino-4-(4-methylbenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-(7-bromo-1-dimethylamino-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;

7-bromo-1-dimethylamino-4-(4-hydroxybenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-(7-bromo-1-dimethylamino-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzoic acid methyl ester;

[4-(7-bromo-1-dimethylamino-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetic acid;

[4-(7-bromo-1-dimethylamino-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetonitrile;

7-bromo-1-dimethylamino-4-(pyrid-3-ylmethyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-1-dimethylamino-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-1-dimethylamino-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-1-dimethylamino-4-(3-pyrid-4-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-1-dimethylamino-4-prop-2-ynyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-1-dimethylamino-4-(3-phenyl-prop-2-ynyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-(7-bromo-1-dimethylamino-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-yl)phenylacetic acid methyl ester;

1-azepan-1-yl-7-methyl-4-pyrid-3-ylmethyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-azepan-1-yl-7-methyl-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-(7-methyl-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;

4-(3,4-dimethoxybenzyl)-7-methyl-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-(7-methyl-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzoic acid methyl ester;

[4-(7-methyl-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetic acid;

7-methyl-4-pyrid-3-ylmethyl-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-methyl-4-(3-phenylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
[4-(7-methyl-5-oxo-1-thiomorpholin-4-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetic acid;  
7-methyl-4-(3-pyrid-3-ylallyl)-1-thiomorpholin-4-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(1-dimethylamino-7-methyl-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
[4-(dimethylamino-methyl-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetic acid;  
1-dimethylamino-7-methyl-4-((E)-3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-dimethylamino-7-methyl-4-(3-pyrid-3-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-dimethylamino-7-methyl-4-(3-pyrid-4-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-8-methyl-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
(4-cyanobenzyl)-dimethylamino-oxo-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinazoline-7-carbonitrile;  
7-hydroxy-4-((E)-3-phenylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-3-(3-phenylallyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
3-allyl-1-azepan-1-yl-7-chloro-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-3-benzyl-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-7-chloro-3-(4-methylbenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-3-(2-chlorobenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-3-(3-chlorobenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-3-(4-chlorobenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-3-(4-bromobenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-3-(4-fluorobenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-3-(4-(trifluoromethyl)benzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-3-(4-cyanobenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-3-(2-methoxybenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-3-(3-methoxybenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(azepan-1-yl)-7-chloro-3-(4-methoxybenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(azepan-1-yl)-7-chloro-3-(3,4-dichlorobenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(azepan-1-yl)-7-chloro-3-(3,4-dimethoxybenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(azepan-1-yl)-7-chloro-3-(2-pyridylmethyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(azepan-1-yl)-7-chloro-3-(3-pyridylmethyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(azepan-1-yl)-7-chloro-3-(2-phenylethyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(azepan-1-yl)-7-chloro-3-[2-(4-methoxyphenyl)ethyl]-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(azepan-1-yl)-7-chloro-3-(3-phenylpropyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-azepan-1-yl-7-chloro-3-(2-oxo-2-phenylethyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(azepan-1-yl)-7-chloro-3-[2-(4-methoxyphenyl)-2-oxoethyl]-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(azepan-1-yl)-7-chloro-3-[2-(4-chlorophenyl)-2-oxoethyl]-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

5-[(1-(azepan-1-yl)-7-chloro-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-3-yl)acetyl]-2-methoxybenzoic acid methyl ester;

1-(azepan-1-yl)-7-bromo-3-(4-chlorobenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(azepan-1-yl)-7-bromo-3-(4-fluorobenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-(1-(azepan-1-yl)-7-bromo-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-3-ylmethyl)benzonitrile;

1-(azepan-1-yl)-7-bromo-3-(3,4-dimethoxybenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

[4-(7-bromo-5-oxo-1-perhydro-azepin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-3-ylmethyl)phenyl]acetic acid;

1-(azepan-1-yl)-7-bromo-3-(pyrid-3-ylmethyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-azepan-1-yl-7-bromo-3-((E)-3-phenylallyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-3-((E)-3-phenylallyl)-1-piperid-1-yl-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-3-(4-chlorobenzyl)-1-(pyrrolidin-1-yl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-3-(4-fluorobenzyl)-1-(pyrrolidin-1-yl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-(7-bromo-5-oxo-1-(pyrrolidin-1-yl)-5H-[1,2,4]triazolo[4,3-a]quinazolin-3-ylmethyl)benzonitrile;  
4-(7-bromo-5-oxo-1-(pyrrolidin-1-yl)-5H-[1,2,4]triazolo[4,3-a]quinazolin-3-ylmethyl)benzoic acid methyl ester;  
7-bromo-3-(4-methoxybenzyl)-1-pyrrolidin-1-yl-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
acetic acid 4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-3-ylmethyl)phenyl ester;  
7-bromo-1-dimethylamino-3-(4-hydroxybenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
3-(benzo[1,3]dioxol-5-ylmethyl)-7-bromo-1-(pyrrolidin-1-yl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-3-(3,5-dimethoxybenzyl)-1-(pyrrolidin-1-yl)-3H-[1,2,4]triazolo- [4,3-a]quinazolin-5-one;  
7-bromo-1-(pyrrolidin-1-yl)-3-(3,4,5-trimethoxybenzyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-3-(1H-imidazol-4-ylmethyl)-1-pyrrolidin-1-yl-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-3-(n-butyl)-1-(pyrrolidin-1-yl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-3-yl)phenylacetic acid methyl ester;  
7-bromo-1-dimethylamino-3-(3-phenylallyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(7-bromo-1-dimethylamino-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-3-yl)phenylacetic acid methyl ester;  
1-(azepan-1-yl)-7-methyl-3-(3-phenylallyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-methyl-3-(3-phenylallyl)-1-(pyrrolidin-1-yl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-3,8-dimethyl-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-8-methyl-3-((E)-3-phenylallyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-hydroxy-3-(3-phenylallyl)-1-(pyrrolidin-1-yl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1,8-bis(azepan-1-yl)-3-(3-phenylallyl)-3H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-4-benzyl-7-bromo-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-(pyrrolidin-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-(butyl-methyl-amino)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-benzyl-1-(pyrrolidin-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-chloro-1-dibutylamino-4-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-chloro-4-methyl-1-(piperid-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-chloro-4-methyl-1-(4-methyl-piperazin-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-chloro-4-methyl-1-(1,8,8-trimethyl-3-azabicyclo[3.2.1]oct-3-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-phenyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-4-benzyl-7-chloro-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-chloro-1-(pyrrolidin-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-chloro-1-(piperid-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-8-chloro-4-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-4-benzyl-8-chloro-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-bromo-4-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-(piperid-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-dimethylamino-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-morpholin-4-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-thiomorpholin-4-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-(4-methylpiperazin-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-(4-phenylpiperazin-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-1-(4-benzylpiperazin-1-yl)-7-bromo-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-(3,6-dihydro-2H-pyrid-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-(2,5-dihydropyrrol-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-(3-hydroxypyrrolidin-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-methylamino-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-iodo-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-4-benzyl-7-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-methyl-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-1-dimethylamino-7-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-methyl-1-thiomorpholin-4-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-4-benzyl-8-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-4-benzyl-7-methoxy-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-methoxy-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-benzyl-5-oxo-1-pyrrolidin-1-yl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinazoline-7-carbonitrile;  
1-azepan-1-yl-4-benzyl-7-nitro-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-4-benzyl-7-chloro-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-4-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-4-benzyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-6-chloro-4-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-ethyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-chloro-4-methyl-1-(pyrrolidin-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-chloro-4-methyl-1-(morpholin-4-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azocan-1-yl)-7-chloro-4-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-chloro-1-(3,4-dihydro-2H-quinolin-1-yl)-4-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-chloro-1-(3,4-dihydro-1H-isoquinolin-2-yl)-4-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(4-benzylpiperid-1-yl)-7-chloro-4-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-chloro-4-methyl-1-(1,3,3-trimethyl-6-azabicyclo[3,2,1]oct-6-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-fluoro-4-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-iodo-4-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-methoxy-4-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-(ethylmethylamino)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-1-diethylamino-7-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-pyrrol-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(4-aminobenzyl)-7-bromo-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-hydroxy-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(7-hydroxy-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
N-(4-benzyl-5-oxo-1-pyrrolidin-1-yl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinazolin-7-yl)acetamide;  
N-[5-oxo-4-(3-phenylallyl)-1-pyrrolidin-1-yl-4,5-dihydro-[1,2,4]triazolo[4,3-a]quinazolin-7-yl]acetamide;  
7-amino-4-((E)-3-phenylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;



7-amino-1-azepan-1-yl-4-benzyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-amino-4-benzyl-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(7-amino-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
7-amino-4-((E)-3-pyrid-3-ylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(amino-dimethylamino-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
7-amino-1-dimethylamino-4-((E)-3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-methylamino-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(7-methylamino-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
4-benzyl-8-methylamino-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-ethylamino-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-isopropylamino-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
N-(4-benzyl-5-oxo-1-pyrrolidin-1-yl-4,5-dihydro[1,2,4]triazolo[4,3-a]quinazolin-7-yl)-methanesulphonamide;  
4-benzyl-7-dimethylamino-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-1-dimethylamino-5-oxo-4,5-dihydro[1,2,4]triazolo[4,3-a]quinazoline-7-carbonitrile;  
4-benzyl-5-oxo-1-pyrrolidin-1-yl-4,5-dihydro[1,2,4]triazolo[4,3-a]quinazoline-7-carboxylic acid;  
[4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetic acid methyl ester;  
2-[4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]-N-methylacetamide;  
2-[4-(7-bromo-1-dimethylamino-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetamide;  
2-[4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]-N,N-dimethylacetamide;  
2-[4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]-N-hydroxyacetamide;  
4-(1-dimethylamino-7-methyl-5-thioxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;

4-(7-bromo-1-dimethylamino-5-thioxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
1-dimethylamino-7-methyl-4-(3-pyrid-3-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazoline-5-thione; or  
4-benzyl-7-(N,N-dimethylsulphonylamino)-1-(pyrrolidin-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one.

42. (Previously presented): A compound of claim 35 which is  
1-(azepan-1-yl)-7-chloro-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-1-dimethylamino-4-((E)-3-pyrid-3-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(4-chlorobenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(4-fluorobenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(3,4-dimethoxybenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(3-pyridylmethyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-bromo-4-(4-chlorophenylmethyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(1-azepan-1-yl-7-bromo-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
1-azepan-1-yl-7-bromo-4-(3,4-dimethoxybenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-bromo-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-7-bromo-4-((E)-3-pyrid-3-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-7-bromo-4-(3-pyrid-4-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(4-methylbenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(4-chlorobenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(4-fluorobenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)-benzoic acid methyl ester;  
7-bromo-4-(4-nitrobenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-(4-methoxybenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

acetic acid 4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl ester;

7-bromo-4-(4-hydroxybenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-(3,4-dimethoxybenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(pyrrolidin-1-yl)-7-bromo-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-[(E)-3-(4-chlorophenyl)allyl]-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-[3-(4-methoxyphenyl)allyl]-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-(3-pyrid-3-ylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-[(E)-3-pyrid-4-ylallyl]-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-4-(3,4-dimethoxybenzyl)-1-piperid-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-(piperid-1-yl)-7-bromo-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-1-dimethylamino-4-(4-methylbenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-(7-bromo-1-dimethylamino-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;

7-bromo-1-dimethylamino-4-(4-hydroxybenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-(bromo-dimethylamino-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzoic acid methyl ester;

[4-(7-bromo-1-dimethylamino-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetonitrile;

7-bromo-1-dimethylamino-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

7-bromo-1-dimethylamino-4-(3-phenyl-prop-2-ynyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

1-azepan-1-yl-7-methyl-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-(3,4-dimethoxybenzyl)-7-methyl-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;


[4-(7-methyl-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetic acid;  
7-methyl-4-(3-phenylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
[4-(dimethylamino-methyl-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetic acid;  
1-dimethylamino-7-methyl-4-((E)-3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-dimethylamino-7-methyl-4-(3-pyrid-3-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
[4-(7-bromo-5-oxo-1-perhydroazepin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-3-ylmethyl)phenyl]acetic acid;  
4-benzyl-7-bromo-1-(pyrrolidin-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-bromo-1-(2,5-dihydropyrrol-1-yl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-iodo-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-4-benzyl-7-methyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(4-aminobenzyl)-7-bromo-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-amino-4-((E)-3-phenylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-amino-1-azepan-1-yl-4-benzyl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-amino-4-((E)-3-pyrid-3-ylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-amino-1-dimethylamino-4-((E)-3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-methylamino-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(7-methylamino-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
4-benzyl-8-methylamino-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-ethylamino-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-isopropylamino-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
[4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetic acid methyl ester;  
2-[4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]-N-methylacetamide;  
2-[4-(7-bromo-1-dimethylamino-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetamide;

2-[4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]-N,N-dimethylacetamide;  
2-[4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]-N-hydroxyacetamide; or  
1-dimethylamino-7-methyl-4-(3-pyrid-3-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazoline-5-thione.

43. (Previously presented): A compound of claim 35 which is  
bromo-dimethylamino-((E)-3-pyrid-3-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(3,4-dimethoxybenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-chloro-4-(3-pyridylmethyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(1-azepan-1-yl-7-bromo-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
1-azepan-1-yl-7-bromo-4-(3,4-dimethoxybenzyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(azepan-1-yl)-7-bromo-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-7-bromo-4-((E)-3-pyrid-3-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-7-bromo-4-(3-pyrid-4-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(4-methylbenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(4-chlorobenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(3,4-dimethoxybenzyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(pyrrolidin-1-yl)-7-bromo-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-4-(3-pyrid-3-ylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-(piperid-1-yl)-7-bromo-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(7-bromo-1-dimethylamino-5-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
4-(bromo-dimethylamino-oxo-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)-benzoic acid methyl ester;  
7-bromo-1-dimethylamino-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-bromo-1-dimethylamino-4-(3-phenylprop-2-ynyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
1-azepan-1-yl-7-methyl-4-(3-phenylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;

4-(3,4-dimethoxybenzyl)-7-methyl-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-methyl-4-(3-phenylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-amino-4-((E)-3-phenylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
7-amino-4-((E)-3-pyrid-3-ylallyl)-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-benzyl-7-methylamino-1-pyrrolidin-1-yl-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-one;  
4-(7-methylamino-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)benzonitrile;  
[4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]acetic acid methyl ester;  
2-[4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]-N-methylacetamide;  
2-[4-(7-bromo-5-oxo-1-pyrrolidin-1-yl-5H-[1,2,4]triazolo[4,3-a]quinazolin-4-ylmethyl)phenyl]-N,N-dimethylacetamide; or  
1-dimethylamino-7-methyl-4-(3-pyrid-3-ylallyl)-4H-[1,2,4]triazolo[4,3-a]quinazolin-5-thione.


44. (Previously presented): A compound of Formula III,



wherein

- $X_1$  and  $X_2$  are independently
- hydrogen, hydroxy, halogen, amino, nitro, mercapto, cyano or carboxyl;
- $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy or  $-S(O)_mR_8$ , said alkyl and alkoxy being optionally substituted on carbon with one to three halogen;
- $-CO-Q_1-Q_2-Q_3$ ;
- $-NH-R_1$ ; or
- $-NR_2R_3$ ;

- the dashed lines represent optional double bonds ;
  - $R_6$  and  $R_7$  are taken together with the atoms to which they are attached to form a 5- or 6-membered ring, said ring optionally containing one or two additional N or one or two O or S, said ring being optionally substituted with one, two or three (C<sub>1</sub>-C<sub>6</sub>)thioalkyl, mercapto or halogen;
- $m$  is 0, 1 or 2;
- $R_8$  is (C<sub>1</sub>-C<sub>6</sub>)alkyl, said alkyl being optionally substituted with one to three halogen;
- Q<sub>1</sub>- is a bond, -O-,



-Q<sub>2</sub>- is:

- a) -(CH<sub>2</sub>)<sub>q</sub>;
- b) -(CH<sub>2</sub>-CH<sub>2</sub>-O)<sub>r</sub>;

-Q<sub>3</sub> is: -H, -OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, -O-CO-X<sub>3</sub>, -NHX<sub>3</sub>, or -NX<sub>3</sub>X<sub>4</sub>;

$p$  is 0, 1, 2 or 3;

$Z_1$  is CH, N, O or S;

$q$  is 0, 1, 2, 3, or 4;

$r$  is 2, 3, or 4;

$X_3$  and  $X_4$  are taken separately and are independently (C<sub>1</sub>-C<sub>6</sub>)alkyl; or

$X_3$  and  $X_4$  are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7-membered ring, said ring containing one to three additional hetero atoms selected from O, S and N;


$R_1$  is (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three halogen, hydroxy, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>; and

$R_2$  and  $R_3$  are taken separately and are independently (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three hydroxy, halogen, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;

or

$R_2$  and  $R_3$  are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7- membered ring, said ring containing one to three O, S or N, said ring being optionally bridged with a (C<sub>1</sub>-C<sub>6</sub>)alkyl which may be gem-dialkylated or substituted with one to three hydroxy, oxo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>.


45. (Previously presented): A compound of Formula IV,



- wherein
- $A_1$  is O or S ;
- $X_1$  and  $X_2$  are independently
- hydrogen, hydroxy, halogen, amino, nitro, mercapto, cyano or carboxyl;
- $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy or  $-S(O)_mR_8$ , said alkyl and alkoxy being optionally substituted on carbon with one to three halogen;
- $-CO-Q_1-Q_2-Q_3$ ;
- $-NH-R_1$ ; or
- $-NR_2R_3$ ;
- $R_4$  and  $R_5$  are taken separately, are identical, and are  $(C_1-C_6)$ alkyl; or
- $R_4$  and  $R_5$  are taken separately, are different, and are aryl $(C_1-C_6)$ alkyl,  $(C_3-C_7)$ cycloalkyl or  $(C_3-C_7)$ cycloalkyl $(C_1-C_6)$ alkyl; or
- $R_4$  and  $R_5$  are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7-membered saturated or partially unsaturated ring, said ring optionally containing one to three hetero atoms selected from O, S and N, said ring being optionally substituted with  $(C_1-C_6)$ alkyl, hydroxy or  $(C_1-C_6)$ alkoxy, said ring being optionally bridged with a  $(C_1-C_6)$ alkyl which may be gem-di $(C_1-C_6)$ alkylated or substituted with one to three hydroxy, oxo,  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy, phenyl $(C_1-C_6)$ alkyl or  $CO-Q_1-Q_2-Q_3$ , said ring being optionally fused via two adjacent atoms shared with another ring selected from phenyl and heteroaryl, said heteroaryl ring containing four to eight carbon atoms which may be optionally replaced with one to three hetero atoms selected from O, S and N;
- m is 0, 1 or 2;
- $R_8$  is  $(C_1-C_6)$ alkyl, said alkyl being optionally substituted with one to three halogen;



-Q<sub>1</sub>- is a bond, -O-,




-Q<sub>2</sub>- is:

a) -(CH<sub>2</sub>)<sub>q</sub>;

b) -(CH<sub>2</sub>-CH<sub>2</sub>-O)<sub>r</sub>;

-Q<sub>3</sub> is: -H, -OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, -O-CO-X<sub>3</sub>, -NHX<sub>3</sub>, or



R<sub>1</sub> is (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three halogen, hydroxy, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;

R<sub>2</sub> and R<sub>3</sub> are taken separately and are independently (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three hydroxy, halogen, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;  
or

R<sub>2</sub> and R<sub>3</sub> are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7- membered ring, said ring containing one to three O, S or N, said ring being optionally bridged with a (C<sub>1</sub>-C<sub>6</sub>)alkyl which may be gem-dialkylated or substituted with one to three hydroxy, oxo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;

p is 0, 1, 2 or 3;

Z<sub>1</sub> is CH, N, O or S;


q is 0, 1, 2, 3, or 4;

r is 2, 3, or 4; and

X<sub>3</sub> and X<sub>4</sub> are taken separately and are independently (C<sub>1</sub>-C<sub>6</sub>)alkyl; or


X<sub>3</sub> and X<sub>4</sub> are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7-membered ring, said ring containing one to three additional hetero atoms selected from O, S and N.

46. (Previously presented): A compound of Formula V,



wherein


- $A_1$  is O or S ;
- $X_1$  and  $X_2$  are independently
  - hydrogen, hydroxy, halogen, amino, nitro, mercapto, cyano or carboxyl;
  - $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy or  $-S(O)_mR_8$ , said alkyl and alkoxy being optionally substituted on carbon with one to three halogen;
  - $-CO-Q_1-Q_2-Q_3$ ;
  - $-NH-R_1$ ; or
  - $-NR_2R_3$ ;
- R is
  - $(C_1-C_6)$ alkyl,  $(C_2-C_6)$ alkenyl,  $(C_2-C_6)$ alkynyl, aryl $(C_2-C_6)$ alkynyl, or 2-, 3- or 4-pyridyl $(C_1-C_6)$ alkyl optionally substituted with  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy, hydroxy, halogen or amino; or



m is 0, 1 or 2;

$R_8$  is  $(C_1-C_6)$ alkyl, said alkyl being optionally substituted with one to three halogen;

$-Q_1-$  is a bond,  $-O-$ ,




-Q<sub>2</sub>- is:

a) -(CH<sub>2</sub>)<sub>q</sub>-;

b) -(CH<sub>2</sub>-CH<sub>2</sub>-O)<sub>r</sub>;

-Q<sub>3</sub> is: -H, -OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, -O-CO-X<sub>3</sub>, -NHX<sub>3</sub>, or



R<sub>1</sub> is (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three halogen, hydroxy, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;

R<sub>2</sub> and R<sub>3</sub> are taken separately and are independently (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three hydroxy, halogen, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;  
or

R<sub>2</sub> and R<sub>3</sub> are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7- membered ring, said ring containing one to three O, S or N, said ring being optionally bridged with a (C<sub>1</sub>-C<sub>6</sub>)alkyl which may be gem-dialkylated or substituted with one to three hydroxy, oxo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;

n is 1, 2, 3, 4 or 5;

Ar is a 5- or 6-membered aromatic ring containing 0 to 3 hetero atoms selected from O, S and N;

Y<sub>1</sub>, Y<sub>2</sub> and Y<sub>3</sub> are independently

- hydrogen, hydroxy, mercapto, amino, nitro, halogen, -NHR<sub>1</sub>, -NR<sub>2</sub>R<sub>3</sub>,

-(CH<sub>2</sub>)<sub>5</sub>CN or -(CH<sub>2</sub>)<sub>5</sub> CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;

-(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -S(O)<sub>m</sub>R<sub>8</sub>;

s is 0, 1, 2, 3, 4, 5 or 6 ;

p is 0, 1, 2 or 3;

Z<sub>1</sub> is CH, N, O or S;

q is 0, 1, 2, 3, or 4;

r is 2, 3, or 4; and


X<sub>3</sub> and X<sub>4</sub> are taken separately and are independently (C<sub>1</sub>-C<sub>6</sub>)alkyl; or

$X_3$  and  $X_4$  are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7-membered ring, said ring containing one to three additional hetero atoms selected from O, S and N;

$X_5$  is halogen,  $-\text{OCOX}_7$ ,  $-\text{OSO}_2\text{X}_7$  or  $-\text{SO}_2\text{X}_7$ ; and


$X_7$  is  $(\text{C}_1\text{-C}_6)$ alkyl or aryl;

provided that when  $X_1$  and  $X_2$  are each H,  $A_1$  is O, R is



Y1 and Y2 are each H, and Y3 is halo, then  $X_5$  is not  $-\text{SO}_2\text{X}_7$ .

47. (Currently amended): A process for preparing a compound of Formula I or Formula II,




wherein

~~$A_4$  is O or S;~~


- $X_1$  and  $X_2$  are independently
- hydrogen, hydroxy, halogen, amino, nitro, mercapto, cyano or carboxyl;
- $(\text{C}_1\text{-C}_6)$ alkyl,  $(\text{C}_1\text{-C}_6)$ alkoxy or  $-\text{S}(\text{O})_m\text{R}_8$ , said alkyl and alkoxy being optionally substituted on carbon with one to three halogen;
- $-\text{CO-Q}_1\text{-Q}_2\text{-Q}_3$ ;
- $-\text{NH-R}_1$ ; or
- $-\text{NR}_2\text{R}_3$ ;
- R is

- (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>2</sub>-C<sub>6</sub>)alkenyl, (C<sub>2</sub>-C<sub>6</sub>)alkynyl, aryl(C<sub>2</sub>-C<sub>6</sub>)alkynyl, or 2-, 3- or 4-pyridyl(C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, hydroxy, halogen or amino; or

-




- R<sub>4</sub> and R<sub>5</sub> are taken separately, are identical, and are (C<sub>1</sub>-C<sub>6</sub>)alkyl; or
- R<sub>4</sub> and R<sub>5</sub> are taken separately, are different, and are aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl or (C<sub>3</sub>-C<sub>7</sub>)cycloalkyl(C<sub>1</sub>-C<sub>6</sub>)alkyl; or
- R<sub>4</sub> and R<sub>5</sub> are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7-membered saturated or partially unsaturated ring, said ring optionally containing one to three hetero atoms selected from O, S and N, said ring being optionally substituted with (C<sub>1</sub>-C<sub>6</sub>)alkyl, hydroxy or (C<sub>1</sub>-C<sub>6</sub>)alkoxy, said ring being optionally bridged with a (C<sub>1</sub>-C<sub>6</sub>)alkyl which may be gem-di(C<sub>1</sub>-C<sub>6</sub>)alkylated or substituted with one to three hydroxy, oxo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, phenyl(C<sub>1</sub>-C<sub>6</sub>)alkyl or CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>, said ring being optionally fused via two adjacent atoms shared with another ring selected from phenyl and heteroaryl, said heteroaryl ring containing four to eight carbon atoms which may be optionally replaced with one to three hetero atoms selected from O, S and N;
- m is 0, 1 or 2;
- R<sub>8</sub> is (C<sub>1</sub>-C<sub>6</sub>)alkyl, said alkyl being optionally substituted with one to three halogen;
- Q<sub>1</sub>- is a bond, -O-,



-Q<sub>2</sub>- is:

- a) -(CH<sub>2</sub>)<sub>q</sub>;
- b) -(CH<sub>2</sub>-CH<sub>2</sub>-O)<sub>r</sub>;

-Q<sub>3</sub> is: -H, -OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, -O-CO-X<sub>3</sub>, -NHX<sub>3</sub>, or



R<sub>1</sub> is (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three halogen, hydroxy, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;

R<sub>2</sub> and R<sub>3</sub> are taken separately and are independently (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three hydroxy, halogen, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;  
or

R<sub>2</sub> and R<sub>3</sub> are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7- membered ring, said ring containing one to three O, S or N, said ring being optionally bridged with a (C<sub>1</sub>-C<sub>6</sub>)alkyl which may be gem-dialkylated or substituted with one to three hydroxy, oxo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;

n is 1, 2, 3, 4 or 5;

Ar is a 5- or 6-membered aromatic ring containing 0 to 3 hetero atoms selected from O, S and N;

Y<sub>1</sub>, Y<sub>2</sub> and Y<sub>3</sub> are independently

- hydrogen, hydroxy, mercapto, amino, nitro, halogen, -NHR<sub>1</sub>, -NR<sub>2</sub>R<sub>3</sub>,
- (CH<sub>2</sub>)<sub>s</sub>CN or -(CH<sub>2</sub>)<sub>s</sub> CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;
- (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -S(O)<sub>m</sub>R<sub>8</sub>;

s is 0, 1, 2, 3, 4, 5 or 6 ;

p is 0, 1, 2 or 3;


Z<sub>1</sub> is CH, N, O or S;

q is 0, 1, 2, 3, or 4;

r is 2, 3, or 4; and

X<sub>3</sub> and X<sub>4</sub> are taken separately and are independently (C<sub>1</sub>-C<sub>6</sub>)alkyl; or

$X_3$  and  $X_4$  are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7-membered ring, said ring containing one to three additional hetero atoms selected from O, S and N;  
comprising reacting a compound of Formula IV,




wherein  $X_1$ ,  $X_2$ ,  $R_4$  and  $R_5$  are as defined hereinabove,  
with a compound of the formula



wherein  $X'$  is halogen,  $-OCOX_7$  or  $-OSO_2X_7$  and  $X_7$  is  $(C_1-C_6)$ alkyl or aryl group ;  
to afford a compound of Formula I and its corresponding isomer of Formula II; and,  
optionally, separating said compound of Formula I and Formula II from each other.

48. (Currently amended): A process for a compound of Formula I,




wherein

—  $A_4$  is O or S;


- $X_1$  and  $X_2$  are independently
- hydrogen, hydroxy, halogen, amino, nitro, mercapto, cyano or carboxyl;
- $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy or  $-S(O)_mR_8$ , said alkyl and alkoxy being optionally substituted on carbon with one to three halogen;

- $-\text{CO}-\text{Q}_1-\text{Q}_2-\text{Q}_3$ ;
- $-\text{NH}-\text{R}_1$ ; or
- $-\text{NR}_2\text{R}_3$ ;
- R is
  - $(\text{C}_1-\text{C}_6)\text{alkyl}$ ,  $(\text{C}_2-\text{C}_6)\text{alkenyl}$ ,  $(\text{C}_2-\text{C}_6)\text{alkynyl}$ ,  $\text{aryl}(\text{C}_2-\text{C}_6)\text{alkynyl}$ , or 2-, 3- or 4-pyridyl $(\text{C}_1-\text{C}_6)\text{alkyl}$  optionally substituted with  $(\text{C}_1-\text{C}_6)\text{alkyl}$ ,  $(\text{C}_1-\text{C}_6)\text{alkoxy}$ , hydroxy, halogen or amino; or



- $\text{R}_4$  and  $\text{R}_5$  are taken separately, are identical, and are  $(\text{C}_1-\text{C}_6)\text{alkyl}$ ; or
- $\text{R}_4$  and  $\text{R}_5$  are taken separately, are different, and are  $\text{aryl}(\text{C}_1-\text{C}_6)\text{alkyl}$ ,  $(\text{C}_3-\text{C}_7)\text{cycloalkyl}$  or  $(\text{C}_3-\text{C}_7)\text{cycloalkyl}(\text{C}_1-\text{C}_6)\text{alkyl}$ ; or
- $\text{R}_4$  and  $\text{R}_5$  are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7-membered saturated or partially unsaturated ring, said ring optionally containing one to three hetero atoms selected from O, S and N, said ring being optionally substituted with  $(\text{C}_1-\text{C}_6)\text{alkyl}$ , hydroxy or  $(\text{C}_1-\text{C}_6)\text{alkoxy}$ , said ring being optionally bridged with a  $(\text{C}_1-\text{C}_6)\text{alkyl}$  which may be gem-di $(\text{C}_1-\text{C}_6)\text{alkylated}$  or substituted with one to three hydroxy, oxo,  $(\text{C}_1-\text{C}_6)\text{alkyl}$ ,  $(\text{C}_1-\text{C}_6)\text{alkoxy}$ , phenyl $(\text{C}_1-\text{C}_6)\text{alkyl}$  or  $\text{CO}-\text{Q}_1-\text{Q}_2-\text{Q}_3$ , said ring being optionally fused via two adjacent atoms shared with another ring selected from phenyl and heteroaryl, said heteroaryl ring containing four to eight carbon atoms which may be optionally replaced with one to three hetero atoms selected from O, S and N;
- m is 0, 1 or 2;
- $\text{R}_8$  is  $(\text{C}_1-\text{C}_6)\text{alkyl}$ , said alkyl being optionally substituted with one to three halogen;
- $-\text{Q}_1-$  is a bond,  $-\text{O}-$ ,






-Q<sub>2</sub>- is:

a) -(CH<sub>2</sub>)<sub>q</sub>;

b) -(CH<sub>2</sub>-CH<sub>2</sub>-O)<sub>r</sub>;

-Q<sub>3</sub> is: -H, -OH, (C<sub>1</sub>-C<sub>6</sub>)alkoxy, -O-CO-X<sub>3</sub>, -NHX<sub>3</sub>, or



R<sub>1</sub> is (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three halogen, hydroxy, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;

R<sub>2</sub> and R<sub>3</sub> are taken separately and are independently (C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three hydroxy, halogen, cyano, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;  
or

R<sub>2</sub> and R<sub>3</sub> are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7- membered ring, said ring containing one to three O, S or N, said ring being optionally bridged with a (C<sub>1</sub>-C<sub>6</sub>)alkyl which may be gem-dialkylated or substituted with one to three hydroxy, oxo, (C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;

n is 1, 2, 3, 4 or 5;

Ar is a 5- or 6-membered aromatic ring containing 0 to 3 hetero atoms selected from O, S and N;

Y<sub>1</sub>, Y<sub>2</sub> and Y<sub>3</sub> are independently

- hydrogen, hydroxy, mercapto, amino, nitro, halogen, -NHR<sub>1</sub>, -NR<sub>2</sub>R<sub>3</sub>,

-(CH<sub>2</sub>)<sub>s</sub>CN or -(CH<sub>2</sub>)<sub>s</sub> CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub>;

-(C<sub>1</sub>-C<sub>6</sub>)alkyl, (C<sub>1</sub>-C<sub>6</sub>)alkoxy or -S(O)<sub>m</sub>R<sub>8</sub>;

s is 0, 1, 2, 3, 4, 5 or 6 ;

p is 0, 1, 2 or 3;


Z<sub>1</sub> is CH, N, O or S;

q is 0, 1, 2, 3, or 4;

r is 2, 3, or 4; and

X<sub>3</sub> and X<sub>4</sub> are taken separately and are independently (C<sub>1</sub>-C<sub>6</sub>)alkyl; or

$X_3$  and  $X_4$  are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7-membered ring, said ring containing one to three additional hetero atoms selected from O, S and N;  
comprising reacting a compound of Formula V,



wherein

wherein  $X_1$ ,  $X_2$  and R are as defined hereinabove and  $X_5$  is halogen,  $-OCOX_7$ ,  $-OSO_2X_7$  or  $-SO_2X_7$ ; and  
 $X_7$  is  $(C_1-C_6)$ alkyl or aryl,  
with a compound of the formula




wherein

- $R_4$  and  $R_5$  are taken separately, are identical, and are  $(C_1-C_6)$ alkyl; or
- $R_4$  and  $R_5$  are taken separately, are different, and are aryl $(C_1-C_6)$ alkyl,  $(C_3-C_7)$ cycloalkyl or  $(C_3-C_7)$ cycloalkyl $(C_1-C_6)$ alkyl; or
- $R_4$  and  $R_5$  are taken together with the nitrogen atom to which they are attached to form a 4-, 5-, 6- or 7-membered saturated or partially unsaturated ring, said ring optionally containing one to three hetero atoms selected from O, S and N, said ring being optionally substituted with  $(C_1-C_6)$ alkyl, hydroxy or  $(C_1-C_6)$ alkoxy, said ring being optionally bridged with a  $(C_1-C_6)$ alkyl which may be gem-di $(C_1-C_6)$ alkylated or substituted with one to three hydroxy, oxo,  $(C_1-C_6)$ alkyl,  $(C_1-C_6)$ alkoxy, phenyl $(C_1-C_6)$ alkyl or  $CO-Q_1-Q_2-Q_3$ , said ring being optionally fused via two adjacent atoms shared with another ring selected from phenyl and heteroaryl, said heteroaryl ring containing four to eight carbon atoms which may be optionally replaced with one to three hetero atoms selected from O, S and N;

to obtain said compound of Formula I.


49. (Previously presented): A process of Claim 48 wherein when  $X_1$  is  $-NR_2R_3$  and  $-NR_2R_3$  and  $-NR_4R_5$  are identical, said compound of Formula I is prepared by reacting a compound of general formula VI :




with a compound of the formula



to give a compound of Formula I having the structure of Formula Ia:




50. (Previously presented): A process of Claim 48 wherein when  $X_1$  is  $-NR_2R_3$  and  $-NR_2R_3$  and  $-NR_4R_5$  are different, said compound of Formula I is obtained by reacting a compound of Formula VII :



with a compound of the formula :

HNR<sub>4</sub>R<sub>5</sub>

to afford a compound of Formula I having the structure of Formula Ib:



51. (Previously presented): A pharmaceutical composition comprising a compound of Claim 35 and a pharmaceutically acceptable excipient.

52. (Currently amended): A method of treating a condition or complaint mediated by inhibition of a phosphodiesterase IV receptor in a mammal comprising administering to said mammal a compound of claim 35, a pharmaceutically acceptable salt of said compound or a pharmaceutical composition said compound or said salt and a pharmaceutically acceptable excipient.

53. (Previously presented): A method of Claim 52 wherein said condition is asthma.

54. (Previously presented): A method of Claim 52 wherein said condition is chronic bronchitis or acute pulmonary attack.

55. (Previously presented): A method of Claim 52 wherein said condition is atopic dermatitis.

56. (Previously presented): A method of Claim 52 wherein said condition is pulmonary hypertension.

57. (Previously presented): A method of Claim 52 wherein said condition is pulmonary or cardiac insufficiency.

58. (Previously presented): A method of Claim 52 wherein said condition is psoriasis.

59. (Currently amended): A method of Claim 52 wherein said condition is an inflammatory condition of the digestive system ~~such as haemorrhagic rectocolitis or Crohn's disease.~~

60. (Currently amended): A method of Claim 52 wherein said condition is diabetes, ~~or a condition associated with a high level of TNF- $\alpha$  such as~~ acute respiratory distress syndrome or acute pancreatitis.

61. (Previously presented): A method of Claim 52 wherein said condition is benign hypertrophy of the prostate.

62. (Previously presented): A method of Claim 52 wherein said condition is chosen from rheumatoid arthritis and multiple sclerosis.

63. (Previously presented): A method of Claim 52 wherein said condition is chosen from depression, ischaemia-induced neuronal damage and partial cerebral ischaemia.

64. and 65. (Canceled)


66. (Previously presented): A method for attenuating the development of tolerance or morphine-dependency phenomena in a mammal comprising administering to said mammal a compound of claim 35, a pharmaceutically acceptable salt of said compound or a pharmaceutical composition said compound or said salt and a pharmaceutically acceptable excipient.

67. (Previously presented): A method of reducing loss of behavioral memory in a mammal comprising administering to said mammal a compound of claim 35, a pharmaceutically acceptable salt of said compound or a pharmaceutical composition said compound or said salt and a pharmaceutically acceptable excipient.

68. (Previously presented): A method of preventing premature labor in a mammal comprising administering to said mammal a compound of claim 35, a pharmaceutically acceptable salt of said compound or a pharmaceutical composition said compound or said salt and a pharmaceutically acceptable excipient.


69. (Currently amended): A method of Claim 52 wherein said condition is septicemia ~~septicaemia~~ or multiple organ failure syndrome.

70. (Previously presented): A compound of claim 36 wherein R is




n is 1, 2 or 3; and Y1, Y2 and Y3 are each independently H or methoxy.

71. (Previously presented): A compound of claim 36 wherein R is



n is 1, 2 or 3; Y1 and Y2 are each H; and Y3, substituted at the 4-position, is  $(C_1-C_6)$ alkoxy, amino, nitro, hydroxy,  $-(CH_2)_5CO-Q_1-Q_2-Q_3$ ,  $-(CH_2)_5CN$ , or  $(C_1-C_6)$ alkyl optionally substituted with one to three halo.


72. (Previously presented): A compound of claim 37 wherein R is



n is 1, 2 or 3; and Y1, Y2 and Y3 are each H or methoxy.

73. (Previously presented): A compound of claim 72 wherein Y1, Y2 and Y3, substituted at the 3-, 4- and 5-position, respectively, are each methoxy.

74. (Previously presented): A compound of claim 37 wherein R is



n is 1, 2 or 3; Y1 and Y2 are each H; and  
Y3, substituted at the 4-position, is

(C<sub>1</sub>-C<sub>6</sub>)alkoxy;

amino;

nitro;


hydroxy;

(C<sub>1</sub>-C<sub>6</sub>)alkyl optionally substituted with one to three halo;

-(CH<sub>2</sub>)<sub>s</sub>CO-Q<sub>1</sub>-Q<sub>2</sub>-Q<sub>3</sub> in which s is 0 or 1; Q<sub>1</sub> is O, -NH- or a bond; Q<sub>2</sub> is -  
(CH<sub>2</sub>)<sub>q</sub>-, wherein q is 0, 1, 2, 3 or 4; and Q<sub>3</sub> is H, OH or -NX<sub>3</sub>X<sub>4</sub>; or  
-(CH<sub>2</sub>)<sub>s</sub>-CN wherein s is 0 or 1.

75. (Previously presented): A compound of claim 37 wherein

R is



said N is substituted at the 3-position.

76. (Previously presented): A compound of claim 46 wherein said  
halogen is F, Br or Cl.

77. (Previously presented): A compound of claim 48 wherein said  
halogen is F, Br or Cl.